Drug intelligence / Profile preview

ACE1655

Development stage: Discontinued
Lead developer: Acepodia
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies

Overview

**ACE1655** is an investigational cell therapy developed by Acepodia Biotech, Inc., designed as a CD20 inhibitor for the treatment of B-cell malignancies and hematological malignancies. It leverages Acepodia's antibody-cell conjugation platform to link antitumor antibodies targeting CD20 to the surface of natural killer (NK) cells, enabling precise tumor cell killing without genetic engineering of the cells. The program has been discontinued globally, with prior updates indicating preparation for an investigational new drug application in hematological indications.

Targets

CD20 (B-lymphocyte antigen CD20)

Beyond the preview

Go deeper on ACE1655.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ACE1655.

Explore the full profile